Page last updated: 2024-08-25

almagate and Retrolental Fibroplasia

almagate has been researched along with Retrolental Fibroplasia in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's5 (83.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chandra, P; Sankar, J; Sankar, MJ1
Cataltepe, SU; VanderVeen, DK1
Bhat, V; Mehta, M; Sankar, J; Sankar, MJ; Srinivasan, R1
Autrata, R; Borek, I; Dolezel, Z; Holousová, M; Krejcírová, I; Senková, K1
Mintz-Hittner, HA1
Joussen, AM1

Reviews

4 review(s) available for almagate and Retrolental Fibroplasia

ArticleYear
Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    The Cochrane database of systematic reviews, 2018, 01-08, Volume: 1

    Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Combined Modality Therapy; Cryotherapy; Humans; Infant, Newborn; Intravitreal Injections; Laser Therapy; Randomized Controlled Trials as Topic; Ranibizumab; Retinal Detachment; Retinopathy of Prematurity; Vascular Endothelial Growth Factor A

2018
Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity.
    Seminars in perinatology, 2019, Volume: 43, Issue:6

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Humans; Infant, Newborn; Infant, Premature; Intravitreal Injections; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinopathy of Prematurity; Treatment Outcome; Vascular Endothelial Growth Factor A

2019
Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    The Cochrane database of systematic reviews, 2016, Volume: 2

    Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Combined Modality Therapy; Cryotherapy; Humans; Infant, Newborn; Intravitreal Injections; Laser Therapy; Randomized Controlled Trials as Topic; Retinal Detachment; Retinopathy of Prematurity; Vascular Endothelial Growth Factor A

2016
[Molecular pathogenesis of ocular vascular disease--anti-angiogenesis as a therapeutic concept].
    Deutsche medizinische Wochenschrift (1946), 2007, Jun-08, Volume: 132, Issue:23

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Angiopathies; Diabetic Retinopathy; Humans; Infant, Newborn; Macular Degeneration; Neovascularization, Pathologic; Ranibizumab; Retinal Diseases; Retinopathy of Prematurity; Vascular Diseases

2007

Trials

1 trial(s) available for almagate and Retrolental Fibroplasia

ArticleYear
[Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
    Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti, 2012, Volume: 68, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Combined Modality Therapy; Humans; Infant; Infant, Newborn; Injections, Intraocular; Laser Coagulation; Retinopathy of Prematurity; Vascular Endothelial Growth Factor A

2012

Other Studies

1 other study(ies) available for almagate and Retrolental Fibroplasia

ArticleYear
Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors.
    Early human development, 2012, Volume: 88, Issue:12

    Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Humans; Infant; Infant, Newborn; Infant, Premature; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinopathy of Prematurity; Vascular Endothelial Growth Factors

2012